Trends

Adoption of the Trade Secrets Directive by the European Parliament

Adoption of the Trade Secrets Directive by the European Parliament

Adoption of the Trade Secrets Directive by the European Parliament

15.04.2016 BE law

On 14 April 2016, the European Parliament adopted the new Directive on the protection of undisclosed know-how and business information (Trade Secrets Directive).

According to the press release, the Directive aims to harmonize the definition of “trade secret” in the EU and to offer appropriate means of action and remedies against unlawful acquisition, use and disclosure of confidential commercial information, such as provisional and precautionary measures, injunction and correctives measures or allocation of damages, while ensuring freedom of expression and information as well as protection for whistleblowers.

The Directive also sets up rules to ensure protection of trade secrets, both during and after legal proceedings, including the possibility for judicial authorities to take specific measures (for example restricting access to documents containing trade secrets or to hearings when trade secrets may be disclosed).

The EU Member states will have 24 months to implement this Directive. In the meantime, the proposal has been sent to the Council for approval before its final adoption by the European Parliament.  


 

Team

Related news

21.03.2019 NL law
15 aspects of Brexit you did not know

Short Reads - A Brexit without a deal, or with a deal that does not cover all relevant aspects, is still a potential scenario. We have highlighted a number of unexpected legal consequences of Brexit in such a no deal or incomplete deal scenario.

Read more

21.03.2019 EU law
Ignace Vernimme, Floris ten Have and Manuel Campolini are speakers during the Legal Affairs Conference.

Speaking slot - Ignace Vernimme, IP Partner at Stibbe Brussels, moderates a roundtable discussion on 'second medical use patents'. Manuel Campolini, of-counsel at Stibbe Brussels, co-moderates this session. Floris ten Have, Competition and Regulation Partner at Stibbe Amsterdam, chairs a session on opportunities and challenges for biosimilar medicine developers.

Read more

Our website uses functional cookies for the functioning of the website and analytic cookies that enable us to generate aggregated visitor data. We also use other cookies, such as third party tracking cookies - please indicate whether you agree to the use of these other cookies:

Privacy – en cookieverklaring